Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersDermatology Physician in Santa Ana, CA
NPI: 1346408226Primary Employer
Southern California Dermatology
westdermatology.com
HQ Phone
Get M.D. Jennifer's Phone Numberphone_androidMobile
Get M.D. Jennifer's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2008 - 2025
NY State Medical License
2006 - 2009
American Board of Dermatology
Dermatology
Icahn School Of Medicine At Mount Sinai
icahn.mssm.edu
Residency • Dermatology
2007 - 2010
University of California (Irvine)
Residency • Dermatology
2007 - 2010
UCLA-VA Greater Los Angeles
Internship • Internal Medicine
2005 - 2006
Albert Einstein College of Medicine
einsteinmed.edu
Medical School
Until 2005
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 81 | 182 |
| 2 | 17000Destruction of skin growth | 28 | 35 |
| 3 | 99204New patient office or other outpatient visit, 45-59 minutes | 23 | 23 |
| 4 | 99213Established patient office or other outpatient visit, typically 15 minutes | 21 | 23 |
| 5 | 11102Tangential biopsy of single skin lesion | 20 | 24 |
Authors: Eric Simpson, Peter Lio, Lawrence Eichenfield
Journal: J Dermatolog Treat
Publication Date: 2021-06-28
Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata.
Authors: Edward Maytin, Jerry Shapiro
Publication Date: 2025-01
Inflammatory linear verrucous epidermal nevus responsive to 308-nm excimer laser treatment.
Authors: Stephen Purcell, Naeha Gupta, Emil Tanghetti, Jeffrey Sugarman, Ryan Owen
Journal: Cutis
Lead Sponsor: Boehringer Ingelheim
Intervention / Treatment: DRUG: Placebo to match BI 730357, DRUG: BI 730357
Lead Sponsor: Boehringer Ingelheim
Intervention / Treatment: DRUG: BI 200 mg twice daily, 400 mg total (fed), DRUG: Placebo (fasted), DRUG: BI 25 mg (fasted), DRUG: BI 50 mg (fasted), DRUG: BI 100 mg (fasted), DRUG: BI 200 mg (fasted), DRUG: Placebo (fed), DRUG: BI 400 mg once daily (fed)
Lead Sponsor: Cassiopea SpA
Intervention / Treatment: DRUG: Vehicle cream, DRUG: CB-03-01 cream, 1%